

API Suppliers
US DMFs Filed
CEP/COS Certifications
JDMFs Filed
Other Certificates
Other Suppliers
USA (Orange Book)
Europe
Canada
Australia
South Africa
Uploaded Dossiers
U.S. Medicaid
Annual Reports
0
Details:
Through this MOU, the parties will seek to collaborate on efforts to determine market potential for zoliflodacin, therapeutic value to patients and explore possibilities to enter into future manufacturing and supply agreements.
Lead Product(s): Zoliflodacin,Ceftriaxone,Azithromycin
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: The Global Antibiotic Research and Development Partnership
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement December 17, 2020
Details:
Through this MOU, the parties will seek to collaborate on efforts to determine market potential for zoliflodacin, therapeutic value to patients and explore possibilities to enter into future manufacturing and supply agreements.
Lead Product(s): Zoliflodacin,Ceftriaxone,Azithromycin
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: The Global Antibiotic Research and Development Partnership
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement December 17, 2020
Details:
Azithromycin has antibacterial action as it binds to the 23S rRNA of the 50S ribosomal subunit of susceptible microorganisms inhibiting bacterial protein synthesis and impeding the assembly of the 50S ribosomal subunit.
Lead Product(s): Azithromycin
Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: Zithromax-Generic
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 10, 2023
Details:
BPZE1 is the most advanced next generation pertussis vaccine, designed to overcome deficiencies of current vaccines, including limited durability and the inability to prevent nasopharyngeal Bordetella pertussis infections that lead to transmission.
Lead Product(s): Live-attenuated Bordetella Pertussis Vaccine,Azithromycin,Bordetella Pertussis Challenge Strain
Therapeutic Area: Infections and Infectious Diseases Product Name: BPZE1
Highest Development Status: Phase IIProduct Type: Vaccine
Partner/Sponsor/Collaborator: Knott Partners
Deal Size: $42.8 million Upfront Cash: Undisclosed
Deal Type: Series D Financing September 06, 2022
Details:
Currently, the company caters to anti-infective and pain-management therapeutic areas and has a pipeline of products to enter into the cardio/diabetic and ortho/gynaecology segments, including Veriaz.
Lead Product(s): Azithromycin
Therapeutic Area: Infections and Infectious Diseases Product Name: Veriaz
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Aurobindo Pharma Limited
Deal Size: $22.5 million Upfront Cash: Undisclosed
Deal Type: Acquisition March 28, 2022
Details:
The funding will support a clinical trial to determine whether high doses of inhaled nitric oxide are safe and effective when used in conjunction with current standard-of-care therapies, including amikacin and azithromycin.
Lead Product(s): Nitric Oxide,Amikacin,Azithromycin
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: UndisclosedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Cystic Fibrosis Foundation
Deal Size: $2.1 million Upfront Cash: Undisclosed
Deal Type: Funding February 16, 2021
Details:
The independent Trial Steering Committee concluded that both azithromycin and doxycycline are generally ineffective against early-stage COVID-19 in patients over 50 who are treated with either antibiotic at home.
Lead Product(s): Azithromycin
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 25, 2021
Details:
A preliminary analysis shows no significant difference in the primary endpoint of 28-day mortality (19% azithromycin vs. 19% usual care) There was also no evidence of beneficial effects on the risk of progression to mechanical ventilation or length of hospital stay.
Lead Product(s): Azithromycin,Lopinavir,Ritonavir
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: Phase II/ Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 14, 2020
Details:
Clinical trial of anti-androgen treatment Proxalutamide (GT0918) for the novel coronavirus disease (COVID-19) has reached the initial target of 381 patients enrolment on 25 October 2020. Also, it has demonstrated a positive trend.
Lead Product(s): Proxalutamide,Ivermectin,Azithromycin
Therapeutic Area: Infections and Infec